-
公开(公告)号：EP2868325B1
公开(公告)日：2017-11-01
申请号：EP13813675.9
申请日：2013-07-02
IPC分类号： A61K38/00 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/70 , A61K47/10 , A61K47/12 , A61K47/32 , A61P35/00 , A61P43/00 , C07K7/06
CPC分类号： A61K47/10 , A61K9/0014 , A61K9/7023 , A61K9/7061 , A61K31/195 , A61K31/20 , A61K31/575 , A61K39/0011 , A61K47/12 , A61K47/18 , A61K47/28 , A61K2039/54 , C07K14/4748 , A61K2300/00
-
公开(公告)号：EP2974734B1
公开(公告)日：2018-10-10
申请号：EP14764228.4
申请日：2014-03-11
发明人： NAKATANI, Tomomi , SAITO, Koichi
CPC分类号： C07K14/4748 , A23V2200/308 , A61K9/0019 , A61K9/08 , A61K38/00 , A61K39/0011 , A61K47/12 , C07K7/00
摘要： Provided is an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. An aqueous liquid composition comprising a peptide and an excipient, and having a pH of 3 - 6: wherein the peptide is selected from the group consisting of the following (A) and (B), (A) a peptide consisting of the amino acid sequence shown by Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), and (B) a peptide consisting of the amino acid sequence shown by SEQ ID NO: 1, wherein 1 to 3 amino acids are deleted, substituted and/or added, and having a cytotoxic T cell-inducing ability; and the excipient contains one or more kinds selected from the group consisting of the following (C), (D) and (E), (C) one or more kinds of alpha hydroxy acids selected from the group consisting of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (D) one or more kinds of dicarboxylic acids selected from the group consisting of malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and (E) methionine.
-
公开(公告)号：EP2868325A1
公开(公告)日：2015-05-06
申请号：EP13813675.9
申请日：2013-07-02
IPC分类号： A61K38/00 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/70 , A61K47/10 , A61K47/12 , A61K47/32 , A61P35/00 , A61P43/00 , C07K7/06
CPC分类号： A61K47/10 , A61K9/0014 , A61K9/7023 , A61K9/7061 , A61K31/195 , A61K31/20 , A61K31/575 , A61K39/0011 , A61K47/12 , A61K47/18 , A61K47/28 , A61K2039/54 , C07K14/4748 , A61K2300/00
摘要： An object of the present invention is to provide a transdermal preparation showing more efficient induction of CTL by a WT1 protein-derived cancer antigen peptide.
The present invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide, and an ether-type additive represented by the formula (1):
R 1 -O-R 2 (1)
[wherein R 1 is a hydrocarbon group having 8 - 24 carbon atoms, and
R 2 is a group represented by the formula (2):
or a group represented by the formula (3):
-(CH 2 CH 2 O) m H (3)
wherein m is an integer of 1 - 18],
wherein the additive is liquid at 20°C, to a WT1 protein-derived cancer antigen peptide.摘要翻译： 本发明的目的是提供通过WT1蛋白衍生的癌抗原肽更有效地诱导CTL的透皮制剂。 本发明通过应用含有WT1蛋白衍生的癌抗原肽的透皮制剂和由式（1）表示的醚型添加剂，能够更有效地进行CTL诱导：€ƒ€ƒ€ƒ€ƒ€ ƒ€ƒR1 -OR 2€ƒ€ƒ€ƒ€ƒ（1）[其中R 1是具有8-24个碳原子的烃基，R 2是由式（2）表示的基团：或 由公式（3）表示的组：€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ-（CH 2 CH 2 O）m H€ƒ€ƒ€ƒ€ƒ（3）其中 m为1〜18的整数]，其中所述添加剂在20℃下为液体，与WT1蛋白衍生的癌抗原肽。
-
公开(公告)号：EP1844789B8
公开(公告)日：2014-10-08
申请号：EP06701409.2
申请日：2006-01-19
发明人： SAITO, Koichi , OKAWA, Yusuke
CPC分类号： C07K7/08 , A61K9/0019 , A61K9/107 , A61K39/0011 , A61K47/14 , A61K2039/55566 , C07K7/06
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
